In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its ...

Picking a good dividend stock for your portfolio can be challenging, especially when there are many attractive high-yielding ...

It could prove to be a case of better later than never for the healthcare giant.

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn’t be treated with surgery, dealing a setback to the closely watched ...

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 ...

Can a pharmaceutical company build "power brands" the way consumer giants do? In this exclusive Fortune India: In ...

Pfizer said on Thursday that finance chief Dave Denton will leave ⁠on August 15 to return to the consumer goods industry.

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Pfizer said on Monday its drug for ​a type of lung cancer ‌missed the main goal of improving survival in patients compared to ​a generic drug in ​a late-stage trial.

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...